SG11201900298RA - Heterocyclic compound used as fgfr inhibitor - Google Patents

Heterocyclic compound used as fgfr inhibitor

Info

Publication number
SG11201900298RA
SG11201900298RA SG11201900298RA SG11201900298RA SG11201900298RA SG 11201900298R A SG11201900298R A SG 11201900298RA SG 11201900298R A SG11201900298R A SG 11201900298RA SG 11201900298R A SG11201900298R A SG 11201900298RA SG 11201900298R A SG11201900298R A SG 11201900298RA
Authority
SG
Singapore
Prior art keywords
compound
heterocyclic compound
fgfr
compound used
fgfr inhibitor
Prior art date
Application number
SG11201900298RA
Other languages
English (en)
Inventor
Norman Xianglong Kong
Chao Zhou
Zhixiang Zheng
Original Assignee
Nanjing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Innocare Pharma Tech Co Ltd filed Critical Nanjing Innocare Pharma Tech Co Ltd
Publication of SG11201900298RA publication Critical patent/SG11201900298RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
SG11201900298RA 2016-07-13 2017-06-13 Heterocyclic compound used as fgfr inhibitor SG11201900298RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610550151.3A CN107619388A (zh) 2016-07-13 2016-07-13 作为fgfr抑制剂的杂环化合物
PCT/CN2017/088038 WO2018010514A1 (zh) 2016-07-13 2017-06-13 作为fgfr抑制剂的杂环化合物

Publications (1)

Publication Number Publication Date
SG11201900298RA true SG11201900298RA (en) 2019-02-27

Family

ID=60951887

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201900298RA SG11201900298RA (en) 2016-07-13 2017-06-13 Heterocyclic compound used as fgfr inhibitor
SG10202013038VA SG10202013038VA (en) 2016-07-13 2017-06-13 Heterocyclic compound used as fgfr inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202013038VA SG10202013038VA (en) 2016-07-13 2017-06-13 Heterocyclic compound used as fgfr inhibitor

Country Status (12)

Country Link
US (1) US10590109B2 (zh)
EP (1) EP3489223A4 (zh)
JP (1) JP6896852B2 (zh)
KR (1) KR102386428B1 (zh)
CN (2) CN107619388A (zh)
AU (1) AU2017295628B2 (zh)
CA (1) CA3030070A1 (zh)
MX (1) MX2019000451A (zh)
PH (1) PH12019500036A1 (zh)
RU (1) RU2742485C2 (zh)
SG (2) SG11201900298RA (zh)
WO (1) WO2018010514A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069602C (en) * 2017-08-04 2022-12-06 Abbisko Therapeutics Co., Ltd. Formylpyridine derivative having fgfr4 inhibitory activity, preparation method therefor and use thereof
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
CN108129471A (zh) * 2018-03-20 2018-06-08 韩邦森 一种噻唑取代嘧啶类化合物的合成工艺
BR112021003620A2 (pt) 2018-10-05 2021-05-18 Forma Therapeutics, Inc. pirrolinas fundidas que atuam como inibidoras da protease específica para a ubiquitina 30 (usp30)
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN111039874B (zh) * 2019-12-13 2022-11-04 南开大学 一种2-胺基-4-甲基嘧啶化合物的零废水制备方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2340605C2 (ru) * 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
CN1508130A (zh) * 2002-12-18 2004-06-30 中国科学院大连化学物理研究所 N-苯基-n’-嘧啶基取代脲类衍生物的合成方法
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
ATE400567T1 (de) * 2004-06-23 2008-07-15 Lilly Co Eli Kinaseinhibitoren
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
FR2889526B1 (fr) * 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP1790342A1 (de) * 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US20070173488A1 (en) * 2005-11-16 2007-07-26 Sgx Pharmaceuticals, Inc. Pyrazolothiazole Protein Kinase Modulators
AU2006320440B2 (en) * 2005-12-02 2012-04-05 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
FR2908409B1 (fr) * 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
FR2947546B1 (fr) * 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
WO2013024427A1 (en) * 2011-08-16 2013-02-21 Glenmark Pharmaceuticals S.A. Novel urea derivatives as tec kinase inhibitors and uses thereof
CA2927252C (en) * 2013-10-25 2021-09-28 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
BR112017016817A2 (pt) * 2015-03-25 2018-04-03 Novartis Ag derivados heterocíclicos formilados como inibidores de fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

Also Published As

Publication number Publication date
RU2019100164A (ru) 2020-08-13
CN108349896A (zh) 2018-07-31
MX2019000451A (es) 2019-09-27
CA3030070A1 (en) 2018-01-18
AU2017295628B2 (en) 2021-05-13
US10590109B2 (en) 2020-03-17
RU2019100164A3 (zh) 2020-08-27
AU2017295628A1 (en) 2019-02-21
KR20190032420A (ko) 2019-03-27
KR102386428B1 (ko) 2022-04-14
CN108349896B (zh) 2021-06-01
EP3489223A1 (en) 2019-05-29
PH12019500036A1 (en) 2019-10-28
EP3489223A4 (en) 2020-01-15
JP6896852B2 (ja) 2021-06-30
JP2019522055A (ja) 2019-08-08
US20190144427A1 (en) 2019-05-16
WO2018010514A1 (zh) 2018-01-18
SG10202013038VA (en) 2021-01-28
CN107619388A (zh) 2018-01-23
RU2742485C2 (ru) 2021-02-08

Similar Documents

Publication Publication Date Title
SG11201900298RA (en) Heterocyclic compound used as fgfr inhibitor
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
PH12018500360A1 (en) Heteroaryl derivatives as parp inhibitors
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
MY195427A (en) Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
WO2015168466A8 (en) Inhibitors of lysine specific demethylase-1
MY197116A (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
MX2020013694A (es) Compuestos heterocíclicos como inhibidores de trk.
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
MY188700A (en) Bicyclic ketone sulfonamide compounds
MX369369B (es) Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
WO2015191754A3 (en) Phosphatidylinositol 3-kinase inhibitors
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
PH12017500007A1 (en) Quinolizinone derivatives as p13k inhibitors
EP4252856A3 (en) Novel quinazolinones that inhibit the formation of tau oligomers and their method of use